Scarica l'app Stockscreener
5.03
3.71%
0.18
Pre-mercato:
5.12
0.09
+1.79%
Precedente Chiudi:
$4.85
Aprire:
$4.83
Volume 24 ore:
1.04M
Relative Volume:
0.32
Capitalizzazione di mercato:
$572.99M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-29.31
EPS:
-0.1716
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
+3.07%
1M Prestazione:
+115.88%
6M Prestazione:
+36.31%
1 anno Prestazione:
+69.93%
Intervallo 1D:
$4.64
$5.035
Intervallo di 1 settimana:
$4.53
$5.20
Portata 52W:
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
5.03 | 552.48M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-10 | Iniziato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - Benzinga
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results - Bitget
Contrasting Perspective Therapeutics (CATX) and Its Peers - Defense World
Financial Review: Perspective Therapeutics (CATX) & Its Rivals - Defense World
How Perspective Therapeutics Inc. stock reacts to new regulations2025 Pullback Review & Long-Term Growth Portfolio Plans - mfd.ru
Can Perspective Therapeutics Inc. lead its sector in growthDividend Hike & Low Drawdown Investment Ideas - mfd.ru
Will Perspective Therapeutics Inc. benefit from rising consumer demandJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - mfd.ru
Can Perspective Therapeutics Inc. expand into new marketsLayoff News & Safe Capital Investment Plans - mfd.ru
Activity Recap: Does Perspective Therapeutics Inc stock have upside surprise potentialExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed? - Yahoo Finance
Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline - TipRanks
Perspective Therapeutics prices $175M equity offering; shares up - MSN
Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants - Nasdaq
Perspective Therapeutics (CATX) Raises $175 Million Through Stoc - GuruFocus
Perspective Therapeutics shares rise after $175 million offering By Investing.com - Investing.com South Africa
Perspective Therapeutics shares rise after $175 million offering - Investing.com
Perspective Therapeutics jumps after $175 mln equity offering - TradingView
Perspective Therapeutics (CATX) Announces $175M Public Offering - GuruFocus
Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering - TipRanks
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - marketscreener.com
Perspective Therapeutics taps $175M stock sale to fund cancer radiopharma work - Stock Titan
Brokerages Set Perspective Therapeutics (NASDAQ:CATX) Target Price at $11.17 - Defense World
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX) - Defense World
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates - Yahoo Finance
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space (CATX) - Seeking Alpha
Perspective Therapeutics (CATX) Rating Maintained, Price Target Raised by HC Wainwright & Co. | CATX Stock News - GuruFocus
Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans - Sahm
Perspective Therapeutics (NASDAQ:CATX) Given Average Rating of "Buy" by Analysts - MarketBeat
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright By Investing.com - Investing.com Canada
Perspective Therapeutics (NASDAQ:CATX) Given Outperform Rating at Wedbush - MarketBeat
CATX: Wedbush Reiterates Outperform Rating with Maintained Price Target | CATX Stock News - GuruFocus
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - Sahm
What is the next catalyst for Perspective Therapeutics Inc.2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - mfd.ru
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com Canada
Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next - TechStock²
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Growth Report: Does Perspective Therapeutics Inc stock have upside surprise potential2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4%Time to Sell? - MarketBeat
Can Perspective Therapeutics Inc expand into new marketsQuarterly Trade Review & Precise Buy Zone Identification - baoquankhu1.vn
Signal Recap: Whats the MACD signal for APLSPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Reviewing Perspective Therapeutics (NASDAQ:CATX) & CapsoVision (NASDAQ:CV) - Defense World
Analyzing Carlsmed (NASDAQ:CARL) and Perspective Therapeutics (NASDAQ:CATX) - Defense World
Aug Momentum: Is Perspective Therapeutics Inc part of any major indexRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
CEO Moves: Is Perspective Therapeutics Inc part of any major indexMarket Performance Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Critical Contrast: Perspective Therapeutics (NASDAQ:CATX) and Shoulder Innovations (NYSE:SI) - Defense World
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets
Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat
Short Covering: Can Perspective Therapeutics Inc generate free cash flowEarnings Overview Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.13%
Capitalizzazione:
|
Volume (24 ore):